Stay updated on Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page
- Check3 days agoChange DetectedA site-wide notice about NIH’s terminology transition appears above the study page, and the site revision changes from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe footer site revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedThe page now displays a 403 Forbidden error with minimal navigation (including a Home link). The previously visible study details are replaced by this error page.SummaryDifference17%

- Check38 days agoChange DetectedThe revision label changed from v3.6.6 to v3.7.0. This indicates a newer version of the study documentation rather than a substantive change to the study content.SummaryDifference0.0%

- Check45 days agoChange DetectedA new publication citation is added under Publications, referencing a 2026 Allergy article by Liu et al. on nemolizumab effects in atopic dermatitis. This broadens the study's referenced literature and provides recent external evidence related to the topic.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page's revision label was updated to v3.6.6, replacing the previous v3.6.5 tag. This indicates a minor update to the site's revision history.SummaryDifference0.0%

Stay in the know with updates to Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.